Clinical trials · California
Lung cancer clinical trials in California
We’re tracking 313 recruiting lung cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT01385722Enrolling by invitation
Molecular testing for cancers in the chest
This study looks at the genetic changes (molecular analysis) in certain cancers of the chest. It may help doctors learn more about what drives these cancers and how they might be diagnosed or treated in the future.
Stanford, CaliforniaAges 18 years+ - NCT06561386RecruitingPhase 3
Testing a new drug combo for advanced lung cancer
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
Los Angeles, CaliforniaAges 18 years+ - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Los Alamitos, CaliforniaAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT05987644RecruitingPhase 1/Phase 2
Timing of brain radiation for ALK-positive lung cancer with brain mets
This trial tests whether it is better to delay brain radiation or give it right away in people with ALK-positive lung cancer that has spread to the brain and is causing few or no symptoms. If you are starting alectinib, you may be able to join and help find the best timing for radiation.
Stanford, CaliforniaAges 18 years+ - NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
San Francisco, CaliforniaAges 18 years+ - NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Huntington Beach, CaliforniaAges 18 years+ - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Los Angeles, CaliforniaAges 18–75 - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Beverly Hills, CaliforniaAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06452277RecruitingPhase 3
Testing sevabertinib for advanced HER2-mutated lung cancer
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
Newport Beach, CaliforniaAges 18 years+ - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Burbank, CaliforniaAges 18 years+ - NCT05558904RecruitingPhase 1/Phase 2
PET/CT scan to help find early lung cancer
This trial tests a special PET/CT scan to spot early lung cancer by finding specific body processes linked to cancer. It compares scan results in people with lung nodules that are either cancer (lung adenocarcinoma) or likely benign.
Los Angeles, CaliforniaAges 18 years+ - NCT06345729RecruitingPhase 3
Study of Calderasib and Pembrolizumab for Advanced Lung Cancer
This trial tests a new combination of two drugs (Calderasib and Pembrolizumab) in people with a specific type of advanced lung cancer (non-small cell lung cancer) that has a KRAS G12C mutation and high PD-L1 levels. It aims to see if this treatment can help shrink or control the cancer.
Beverly Hills, CaliforniaAges 18 years+ - NCT05099172RecruitingPhase 1/Phase 2
Study drug for EGFR or HER2-mutated advanced lung cancer
This early-phase study tests a new investigational medicine (BAY2927088) in people with advanced non-small cell lung cancer (NSCLC) that has EGFR and/or HER2 mutations. It’s designed to see how the drug works and what side effects it causes, when standard options have not helped or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT04701476RecruitingPhase 2
Pembrolizumab for advanced colorectal or lung cancer
This study tests pembrolizumab (an immune system medicine) with another treatment (TATE) in people with advanced colorectal or lung cancer that is not driven by certain gene changes. It may help shrink tumors after standard chemotherapy has stopped working.
Orange, CaliforniaAges 18 years+ - NCT05384769Recruiting
Blood test for early lung cancer screening in high-risk people
This study checks whether a blood test (a liquid biopsy) can be used along with standard lung cancer screening to find lung cancer early in people at higher risk. It may help see if the blood test is practical and useful for screening—without needing symptoms.
Duarte, CaliforniaAges 50–80 - NCT06774963RecruitingPhase 1
Study of LNCB74 for advanced solid tumors
This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.
Newport Beach, CaliforniaAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+
Lung cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting lung cancer studies listed above.
- City of Hope Comprehensive Cancer Center · 5 studies
- City of Hope Orange County Lennar Foundation Cancer Center · 3 studies
- University of California, San Francisco · 3 studies
- Beverly Hills Cancer Center · 2 studies
- Hoag Family Cancer Institute · 2 studies
- Local Institution · 2 studies
- San Francisco Oncology Associates · 2 studies
- Stanford University · 2 studies
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung cancer trials in other states
Common questions
- Are there lung cancer clinical trials in California?
- Yes. We're currently tracking 313 recruiting lung cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.